Newland Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Newland Pharmaceutical Co., Ltd.

Why is Newland Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 0.09% and Operating profit at -16.27% over the last 5 years

ROCE(HY) Lowest at 8.16%
INTEREST COVERAGE RATIO(Q) Lowest at 24,872.06
DEBT-EQUITY RATIO (HY) Highest at -46.62 %

Below par performance in long term as well as near term

Along with generating -1.57% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Newland Pharmaceutical Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Newland Pharmaceutical Co., Ltd.

-100.0%

0.31

58.19%

China Shanghai Composite

16.01%

1.03

14.98%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.09%

EBIT Growth (5y)

-16.27%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.49

Sales to Capital Employed (avg)

0.46

Tax Ratio

13.70%

Dividend Payout Ratio

46.09%

Pledged Shares

Institutional Holding

ROCE (avg)

23.84%

ROE (avg)

10.96%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.33

EV to EBIT

31.85

EV to EBITDA

23.50

EV to Capital Employed

5.13

EV to Sales

6.39

PEG Ratio

Dividend Yield

ROCE (Latest)

16.10%

ROE (Latest)

9.34%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

DEBTORS TURNOVER RATIO(HY)

Highest at 2.46 times

RAW MATERIAL COST(Y)

Fallen by 1.83% (YoY

-32What is not working for the Company

ROCE(HY)

Lowest at 8.16%

INTEREST COVERAGE RATIO(Q)

Lowest at 24,872.06

DEBT-EQUITY RATIO (HY)

Highest at -46.62 %

NET SALES(Q)

Lowest at CNY 122.43 MM

OPERATING PROFIT(Q)

Lowest at CNY 12.78 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 10.44 %

PRE-TAX PROFIT(Q)

Lowest at CNY 15.53 MM

NET PROFIT(Q)

Lowest at CNY 13.94 MM

EPS(Q)

Lowest at CNY 0.04

Here's what is working for Newland Pharmaceutical Co., Ltd.

Debtors Turnover Ratio

Highest at 2.46 times and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by 1.83% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Newland Pharmaceutical Co., Ltd.

Net Profit

At CNY 13.94 MM has Fallen at -53.12%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CNY MM)

Interest Coverage Ratio

Lowest at 24,872.06

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Pre-Tax Profit

At CNY 15.53 MM has Fallen at -49.48%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Sales

Lowest at CNY 122.43 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

Fallen at -12.85%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit

Lowest at CNY 12.78 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at 10.44 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit

Lowest at CNY 15.53 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

Lowest at CNY 13.94 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS

Lowest at CNY 0.04

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debt-Equity Ratio

Highest at -46.62 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Non Operating Income

Highest at CNY 0.18 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income